Article
Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer
2023-05-06
Abstract excerpt
<h4>Background: </h4> Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. Thus, overcoming taxane resistant PC is a major clinical need. We previously identified a seven gene network in aggressive CRPC, which includes the mitotic serine threonine kinase BUB1 , a major regulator of the spindle assembly checkpoint (SAC). Alter...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 453eb309-b014-521a-88f3-4fce6b6095a3
- DOI
- 10.1101/2023.05.05.539598
